New factor XIa inhibitor asundexian shows safer stroke prevention beyond aspirin
Key Questions
What is asundexian and how does it prevent strokes?
Asundexian, a factor XIa inhibitor, reduces recurrent ischemic stroke risk by 25% on top of antiplatelets, with no increase in bleeding. It targets non-cardioembolic strokes in patients averaging age 67 with hypertension, diabetes, and polypharmacy.
How does asundexian compare to aspirin for stroke prevention?
Asundexian offers safer protection beyond aspirin by challenging aspirin's bleeding risks while providing superior recurrent stroke reduction. This could signal a guideline shift for secondary prevention.
What are common side effects of blood thinners like asundexian?
Blood thinners like asundexian may cause bruising, but trials showed no bleed increase versus antiplatelets. Monitor for easy bruising or other signs, and consult providers for personalized risks.
Asundexian cuts recurrent ischemic stroke 25% atop antiplatelets with no bleed increase (trial avg age 67); targets non-cardioembolic strokes in HTN/DM/polypharm 60+; signals potential guideline shift challenging aspirin bleeding risks.